Published in JAMA Neurol on April 01, 2014
Body fluid biomarkers in Alzheimer's disease. Ann Transl Med (2015) 1.44
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol (2014) 1.21
An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies. Neurodegener Dis (2015) 0.90
Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. Front Aging Neurosci (2015) 0.87
Motor neuron disease in 2014. Biomarkers for ALS--in search of the Promised Land. Nat Rev Neurol (2014) 0.81
Use of biomarkers in ALS drug development and clinical trials. Brain Res (2014) 0.79
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? Int J Mol Sci (2015) 0.79
Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst) (2015) 0.78
The Mental Status Examination in Patients With Suspected Dementia. Continuum (Minneap Minn) (2016) 0.78
The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research. Psychiatr Clin North Am (2015) 0.76
Biomarkers in the primary progressive aphasias. Aphasiology (2014) 0.75
Back to the tubule: microtubule dynamics in Parkinson's disease. Cell Mol Life Sci (2016) 0.75
New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis. Transl Neurodegener (2015) 0.75
Emerging Diagnostic and Therapeutic Strategies for Tauopathies. Curr Neurol Neurosci Rep (2017) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 15.38
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Spatial transformations of diffusion tensor magnetic resonance images. IEEE Trans Med Imaging (2001) 6.74
A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage (2010) 6.24
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain (2012) 3.43
Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol (2007) 3.16
Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology (2003) 3.14
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol (2005) 3.09
Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol (2009) 2.68
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry (2011) 2.48
The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry (2011) 2.45
CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology (2008) 2.43
Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology (2006) 2.31
Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol (2011) 2.17
Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology (2002) 2.12
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging (2006) 1.92
Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol (2007) 1.91
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol (2000) 1.82
CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology (2010) 1.77
Formal characterization and extension of the linearized diffusion tensor model. Hum Brain Mapp (2005) 1.75
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70
Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology (2006) 1.69
Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology (2011) 1.56
Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology (2008) 1.50
Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol (2012) 1.42
Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry (2005) 1.40
Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol (2008) 1.30
TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol (2008) 1.28
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun (1997) 1.24
Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: relationships with motor disability. J Neurol Neurosurg Psychiatry (2007) 1.24
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med (2011) 1.24
Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett (1999) 1.17
Assessment of white matter tract damage in patients with amyotrophic lateral sclerosis: a diffusion tensor MR imaging tractography study. AJNR Am J Neuroradiol (2010) 1.16
Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol (2012) 1.13
Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol (2011) 1.05
Diffusion tensor imaging in amyotrophic lateral sclerosis: volumetric analysis of the corticospinal tract. AJNR Am J Neuroradiol (2006) 0.98
Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology (2013) 0.95
Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations. Arch Neurol (2003) 0.94
Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int (2009) 0.93
Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett (2003) 0.92
Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. Eur J Neurol (2009) 0.91
Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis Assoc Disord (1998) 0.88
Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. PLoS One (2011) 0.86
CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration. Neurology (2004) 0.85
Quantitative proton magnetic resonance spectroscopy detects abnormalities in dorsolateral prefrontal cortex and motor cortex of patients with frontotemporal lobar degeneration. J Neurol (2009) 0.83
Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov Disord (2010) 0.79
Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand (2005) 0.78